Goodsurance

Drug prices & Part D

Lower prices on 15 drugs arrive in 2027

Medicare's negotiated prices for 15 widely used medicines take effect this coming January. Here is what that changes, and what it does not, for your own pharmacy bill.

By the Goodsurance editorial teamJuly 1, 2026

Starting January 1, 2027, Medicare's first round of negotiated prices on a second set of 15 high cost drugs takes effect. Public reporting has identified the popular diabetes and weight loss medicines Ozempic and Wegovy among them, alongside treatments for other common conditions. Medicare says that if these negotiated prices had been in place in 2024, they would have lowered net Medicare drug spending by about 8.5 billion dollars, or roughly 36 percent on those drugs. This builds on the first ten negotiated prices that took effect in January 2026, and Medicare is still refining the program, with a proposed update published June 12, 2026 and open for public comment through August 17. Here is the honest read for your own wallet. A negotiated price lowers what the Medicare program pays for a drug, which helps hold down overall costs and can ripple into plan pricing. What you personally pay at the pharmacy still depends on your specific plan, its formulary, and where you are in the year. For most people, the bigger everyday protection is the annual cap on out of pocket drug costs, reported at 2,100 dollars for 2026, which limits your total spending on covered drugs no matter how expensive they are. So the takeaway is not to switch anything today. It is to know that lower negotiated prices are coming for these drugs in January, and to compare plans this fall on how they actually cover the medicines you take. The pointed debate over whether negotiation goes far enough or discourages new drug research routes to my65checklist; here the job is to explain what changes in January and what your copay still hinges on.

Medicare's negotiated prices on 15 more drugs, reportedly including Ozempic and Wegovy, take effect January 1, 2027.

In plain words

Medicare can now negotiate the price of some very costly drugs. The first ten lower prices started in January 2026. Now a second group of 15 drugs gets lower prices, starting January 1, 2027. News reports say two of them are the well known drugs Ozempic and Wegovy. Medicare says these prices could cut its drug spending by about 8.5 billion dollars, roughly 36 percent on those drugs. Here is what it means for you. A negotiated price lowers what Medicare pays. What you pay at the pharmacy still depends on your own plan and the time of year. For most people, the bigger help is the yearly limit on what you pay out of pocket for covered drugs, set at 2,100 dollars for 2026. That caps your total no matter how pricey the drug. You do not need to do anything today. Just know the lower prices are coming in January, and when you shop this fall, check how each plan covers the drugs you take.

Source: Centers for Medicare and Medicaid Services
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

CMS Must Send Final Written Price Offers to 15 Drug Makers by September 30 in Third Negotiation Cycle

The final statutory step before drug manufacturers accept or reject Medicare prices arrives this week. CMS must issue written maximum fair price offers by September 30, and manufacturers have until October 31 to respond. Agreed prices would take effect in 2028.

September 23, 2026

Drug prices & Part D

About 140,000 Wellcare Part D Members Were Dropped Mid-Year After Small New Premiums Were Added to Their Previously Free Plans

KFF Health News found that Wellcare terminated tens of thousands of drug plan members in April 2026 when minimal monthly premiums went unpaid, leaving many without prescription coverage and at risk for permanent Medicare drug enrollment penalties.

September 21, 2026

Drug prices & Part D

MedPAC September Meeting Finds IRA Changes Improved Drug Affordability for Enrollees but May Be Accelerating Overall Medicare Part D Spending

Medicare's congressional advisory commission opened its new study cycle in September finding that Inflation Reduction Act drug benefit changes have helped individual beneficiaries while putting upward pressure on total program spending and future premiums.

September 20, 2026

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

September 19, 2026

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026

Drug prices & Part D

Federal Subsidy That Has Held Down Standalone Medicare Drug Plan Premiums for Two Years Is Ending After 2026

CMS is closing the Part D Premium Stabilization Demonstration after 2026, and a KFF analysis warns that people with standalone prescription drug plans in traditional Medicare could face larger premium increases in 2027 than they have seen in recent years.

September 13, 2026